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Abstract
 
Lipoxin (LX) A
 
4
 
 and aspirin-triggered LX (ATL) are endogenous lipids that regulate leukocyte
trafficking via specific LXA
 
4
 
 receptors (ALXRs) and mediate antiinflammation and resolution.
ATL analogues dramatically inhibited human neutrophil (polymorphonuclear leukocyte
[PMN]) responses evoked by a potent necrotactic peptide derived from mitochondria as well as
a rogue synthetic chemotactic peptide. These bioactive lipid analogues and small peptides each
selectively competed for specific 
 
3
 
H-LXA
 
4
 
 binding with recombinant human ALXR, and its
 
N
 
-glycosylation proved essential for peptide but not LXA
 
4
 
 recognition. Chimeric receptors
constructed from receptors with opposing functions, namely ALXR and leukotriene B
 
4
 
 recep-
tors (BLTs), revealed that the seventh transmembrane segment and adjacent regions of ALXR
are essential for LXA
 
4
 
 recognition, and additional regions of ALXR are required for high affin-
ity binding of the peptide ligands. Together, these findings are the first to indicate that a single
seven-transmembrane receptor can switch recognition as well as function with certain chemo-
tactic peptides to inhibitory with ATL and LX (lipid ligands). Moreover, they suggest that
ALXR activation by LX or ATL can protect the host from potentially deleterious PMN re-
sponses associated with innate immunity as well as direct effector responses in tissue injury by
recognition of peptide fragments.
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Introduction
 
Acute inflammation is normally a localized protective re-
sponse where neutrophils (PMNs) play a pivotal role not
only to destroy invading microbes but also to wall off in-
jured tissues (1). Endogenous chemical mediators generated
by the host govern leukocyte trafficking from the vascula-
 
ture to active sites (2), and in this context leukotriene B
 
4
 
 is
among the most potent PMN chemoattractants known (3–
5). Excessive acute inflammation caused by aberrant host
recognition or prolonged activation of effector cells such as
PMNs can release an array of proinflammatory mediators
amplifying diverse cellular responses that acutely can give
rise to reperfusion injury as well as chronic inflammatory
diseases such as rheumatoid arthritis (6, 7). Most lipid media-
tors, including eicosanoids (prostaglandins and leukotrienes),
elicit inflammation and vascular events and thus are held to
be potent proinflammatory mediators (3). Recent results
provide evidence for a new appreciation that certain lipoxy-
genase-derived eicosanoids possess potent “anti-PMN” ac-
tions and antiinflammatory properties (7–10). In particular,
lipoxin (LX)
 
1
 
 A
 
4
 
 and recently identified aspirin-triggered
LXA
 
4
 
 (ATL, endogenous 15-epimer of LXA
 
4
 
) exhibit anti-
inflammatory properties and appear to serve as novel endog-
enous “stop signals” to regulate excessive leukocyte traffick-
ing and possibly deleterious responses of PMNs (7).
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Abbreviations used in this paper:
 
 ALXR, lipoxin A
 
4
 
 receptor; ATL, aspirin-
 
triggered 15-epi-LXA
 
4
 
;
 
 
 
ATLa, ATL analogue(s) [ATLa
 
1
 
: 15(
 
R/S
 
)-methyl-
 
LXA
 
4
 
 methyl ester; ATLa
 
2
 
: 15-epi-16-(
 
para
 
-fluoro)-phenoxy-LXA
 
4
 
 methyl
 
ester]; BLT,
 
 
 
leukotriene B
 
4
 
 receptor; CHO, Chinese hamster ovary; FPR,
 
N
 
-formyl peptide receptor; HEK, human embryonic kidney; LX, lipoxin;
LXA
 
4
 
, 5(
 
S
 
),6(
 
R
 
),15(
 
S)
 
-trihydroxy-7,9,13-trans-11-cis eicosatetraenoic acid;
SAA, serum amyloid protein A. 
1198
 
Lipid Mediators and Peptide Ligands of the Lipoxin A
 
4
 
 Receptor
 
Aspirin is widely used for its antiinflammatory and anal-
gesic properties (11) and also exhibits newly recognized
beneficial actions, including prevention of cardiovascular
diseases and decreasing the incidence of lung, colon, and
breast cancers (12). In addition to inhibiting formation of
both prothrombotic and proinflammatory eicosanoids, as-
pirin-acetylated cyclooxygenase 2 remains active, and upon
cell activation initiates the endogenous generation of anti-
inflammatory 15-epi-LXA
 
4
 
 (15
 
R
 
-LXA
 
4
 
, ATL) (7). Like
other local mediators, LXA
 
4
 
 and ATL are rapidly generated
within seconds to minutes, act locally to evoke cellular re-
sponses, and are rapidly inactivated by further metabolism.
Hence, LXA
 
4 
 
and ATL stable analogues (ATLa) were de-
signed that resist rapid enzymatic inactivation and prolong
their duration of action. These analogues display potent
anti-PMN actions in vitro and in vivo (7, 13–15) and act
via mechanisms that bypass aspirin’s unwanted side effects
(gastric bleeding, etc.), since they act directly on leukocytes
(7) and regulate a cytokine–chemokine axis (16). In this re-
port, we used these new molecular tools (e.g., LXA
 
4 
 
and
ATLa, structures shown in Fig. 1) and found a novel mech-
anism for PMNs in host recognition and evidence for a
unique functional switch to endogenous antiinflammatory
programming.
LXA
 
4
 
 and its carbon-15 epimeric counterpart ATL (e.g.,
15-epi-LXA
 
4
 
) regulate leukocyte responses via interacting
with high affinity (
 
K
 
d 
 
z 
 
0.5 nM) to a G protein–coupled
receptor denoted ALXR (17; for a review, see reference 7).
This receptor is related at the nucleotide sequence level to
both chemokine and chemotactic peptide receptors, such as
 
N
 
-formyl peptide receptor (FPR) (5). However, we (18)
and others (19) found that the ALXR does not effectively
respond to formyl peptide FMLP, unless cells are exposed
to higher pharmacological doses (i.e., 
 
.
 
1–10 
 
m
 
M), sug-
gesting that these are not physiologically relevant ligands.
Along these lines, the nonclassical MHC Ib CD1 binds and
presents both peptides (20) and lipid antigens such as the
long chain fatty acid, mycotic acid, found in mycobacteria
(21). Thus, T cells can recognize a broader array of both
peptide and lipid antigens than previously appreciated. In
view of the diversity of T cell recognition, it was of interest
 
to determine whether effector cell (i.e., PMN) receptors
for antiinflammatory lipid mediators (13), namely ALXR,
could also utilize specific non–lipid-derived ligands.
 
Materials and Methods
 
Materials.
 
The MHC binding peptide (MYFINILTL) and
MMK-1 peptide (LESIFRSLLFRVM) were prepared by custom
synthesis at Research Genetics, Inc. 
 
125
 
I-MHC binding peptide
was prepared by Phoenix Pharmaceuticals, Inc. and purified by
HPLC. The oligonucleotides were synthesized by Integrated
DNA Technologies, Inc. DNA sequence analysis was performed
in the Brigham and Women’s Hospital DNA Sequencing Core.
Restriction enzymes were purchased from Roche Molecular
Biochemicals with the exception of EcoNI, which was from
New England Biolabs.
 
Cloning and Plasmid Construction.
 
The pcDNA3-BLT plas-
mid containing human leukotriene B4 receptor (BLT)
 
2
 
 cDNA
was prepared as described (15). ALXR cDNA was used as de-
scribed (17), and BLT-ALXR chimeric receptors were con-
structed by PCR and restriction digestion. In brief, for B/A
 
254
 
,
ALXR cDNA fragment (796–1055) carrying EcoNI and XhoI
sites on 5
 
9
 
 and 3
 
9
 
 ends, respectively, was obtained by PCR (30
cycles of 94
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, and 72
 
8
 
C for 1 min)
using Taq DNA polymerase (Qiagen) with oligonucleotides
S-EcoNI (5
 
9
 
-gaacctggctgaggccgtctggctcaag-3
 
9
 
) and AS-XhoI (5
 
9
 
-
cttctcgagtcacattgcctgtaac-3
 
9
 
). ALXR fragment was digested with
EcoNI and XhoI (New England Biolabs) and ligated into
EcoNI-XhoI–digested pcDNA3-BLT. The other chimeras were
constructed using this procedure with the oligonucleotides and
restriction enzymes listed in Table I. Each resulting construct
was verified by complete DNA sequence analysis.
 
Cell Culture and Transfection.
 
Human embryonic kidney (HEK)
293 and Chinese hamster ovary (CHO) cells (American Type
Culture Collection) were cultured in DMEM and HAM F-12
medium (BioWhittaker), respectively, supplemented with 10%
fetal bovine serum. Cells were transfected with plasmid DNA
(5 
 
m
 
g) using SuperFect reagent (Qiagen). After 48 h, cells were
placed in DMEM or HAM F-12 with 0.4 mg/ml Geneticin
 
2
 
International Union of Pharmacologic Sciences (IUPHAR) Nomencla-
ture Committee, Dahlén et al. Receptor Compendium: Leukotriene Re-
ceptors, Stockholm, Sweden, November 1999.
 
Table I.
 
Oligonucleotides and Restriction Enzymes for Chimera Construction
 
Chimera Oligonucleotides Restriction enzymes
A
 
55
 
/B Sense: 5
 
9
 
-gggaagcttatggaaaccaacttct-3
 
9
 
HindIII, Eco47III
Antisense: 5
 
9
 
-aacagcgcttcatccggaatccagc-3
 
9
 
B/A
 
62–262
 
/B Sense: 5
 
9
 
-gttagcgctcagtcaccaccatct-3
 
9
 
Eco47III, EcoNI
Antisense: 5
 
9
 
-aacctcagccagggcaaccagttgaa-3
 
9
 
B/A
 
254
 
Sense: 5
 
9
 
-gaacctggctgaggccgtctggctcaag-3
 
9
 
EcoNI, XhoI
Antisense: 5
 
9
 
-cttctcgagtcacattgcctgtaac-3
 
9
 
B/A
 
299
 
Sense: 5
 
9
 
-gtgcgccggcggctttgtgggccaagactt-3
 
9
 
SgrAI, XhoI
Antisense: 5
 
9
 
-cttctcgagtcacattgcctgtaac-3
 
9
 
See Materials and Methods for details. 
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(GIBCO BRL) to select cells expressing transfected receptors.
CHO cells expressing ALXR and Gqo chimera were a gift from
Berlex Biosciences (Richmond, CA).
 
Preparation of [11,12-
 
3
 
H]-LXA
 
4
 
.
 
[11,12-
 
3
 
H]-LXA
 
4
 
-methyl
ester was prepared in collaboration with Schering AG (Berlin,
Germany) using acetylenic-LXA
 
4
 
-methyl ester precursor (pre-
pared with Dr. Nicos A. Petasis, Department of Chemistry, Uni-
versity of Southern California, Los Angeles, CA) essentially as re-
ported (22) and was a gift from Dr. H.D. Perez at Berlex
Biosciences (Richmond, CA). [11,12-
 
3
 
H]-LXA
 
4
 
-methyl ester
was purified in this laboratory using a Hewlett Packard 1100 Se-
ries diode array detector (DAD) equipped with a binary pump
and eluted on a Beckman Ultrasphere C18 column (250 
 
3
 
 4.5
mm, 5 
 
m
 
m) using a mobile phase composed of methanol/water/
acetate (60:39.99:0.01, vol/vol/vol; flow rate 1.0 ml/min) as
phase 1 (0–15 min), a linear gradient (0–30%) with methanol/ac-
etate (99.99:0.01, vol/vol) as phase 2 (15–55 min), and a linear
gradient (30–100%) of methanol/acetate (99.99:0.01, vol/vol) as
phase 3 (55–60 min). To minimize chemical degradation of
[11,12-
 
3
 
H]-LXA
 
4
 
-methyl ester after HPLC chromatography, the
mobile phase was removed under a stream of N
 
2
 
, suspended in
ethanol, and used immediately for binding experiments.
 
Ligand Binding Assay.
 
3
 
H-LXA
 
4
 
 and 
 
3
 
H-LTB
 
4
 
 binding was
performed with freshly isolated human PMNs or HEK293 cells
transfected with ALXR, BLT, or BLT-ALXR chimeras. Cells
were suspended in Dulbecco’s PBS with CaCl
 
2
 
 and MgCl
 
2
 
(DPBS
 
11
 
). Aliquots (0.5 
 
3 
 
10
 
6
 
/ml HEK293 or 5 
 
3 
 
10
 
6
 
/ml
PMNs) were incubated with 1 nM of [11,12-
 
3
 
H]-LXA
 
4
 
(
 
z
 
60,000 cpm, specific activity 
 
z
 
10 Ci/mmol) or [5,6,8,9,11,12,
14,15-
 
3
 
H]-LTB
 
4
 
 (
 
z
 
20,000 cpm, specific activity 
 
z
 
200 Ci/mmol;
New England Nuclear) in the absence or presence of increasing
concentrations of homoligands or other compounds for 30 min at
4
 
8
 
C. The bound and unbound radioligands were separated by fil-
tration through Whatman GF/C glass microfiber filters (Fisher
Scientific). Filters were washed three times with 5 ml of ice-cold
washing buffer (10 mM Tris-HCl, pH 7.6). The radioactivity re-
tained on the filter was determined using a scintillation counter
(Beckman). Nonspecific binding was determined in the presence
of 100 nM of unlabeled homoligands.
 
Functional Assays.
 
Chemotaxis was performed using a mi-
crochamber technique (23). In brief, chemoattractant or vehicle
(RPMI for PMNs and HAM F-12 for CHO cells containing
0.1% ethanol) was added to the lower wells of a 48-well chemo-
taxis chamber (Neuro Probe). For CHO cells, a polycarbonate
membrane with 8-
 
m
 
m-diameter pores (Poretics Corp.) was
coated with fibronectin (10 
 
mg/ml; GIBCO BRL) for 10 min at
378C and then layered on top of the lower wells. For PMNs, a
polycarbonate membrane with 5-mm–diameter pores was used
directly without fibronectin coating. Freshly isolated human
PMNs or CHO cells were incubated with vehicle or ATLa1 (10
nM) for 30 min at 378C and added to the upper wells of the
chemotaxis chamber (5 3 104/well). After incubation for 60
min (for PMNs) or 4 h (for CHO cells) at 378C, polycarbonate
membrane was removed, and cells were scraped from the upper
surface and stained with a Diff-Quik staining kit (Dade Behring).
Cells that had migrated though the membrane were enumerated
by light microscopy. The migration index was calculated as the
mean number of cells that migrated toward medium containing
chemoattractant solution divided by the mean number of cells
that migrated toward the medium containing vehicle only. In
CHO cells, chemotaxis was ranked for the purpose of direct
comparison using FMLP (10 nM), which evoked chemotaxis of
CHO cells expressing FPR as 100% chemotaxis.
Changes in PMN extracellular acidification were evaluated
using a Cytosensor® microphysiometer (Molecular Devices) and
computer workstation (24), and murine air pouch leukocyte
traffic was performed as described (14).
Statistical Analysis. Results were expressed as the mean 6
SEM, and Student’s t test was performed with P , 0.05 taken as
statistically significant.
Results and Discussion
Results in Fig. 2 demonstrate that the mitochondria pep-
tide fragment MYFINILTL (structures shown in Fig. 1)
derived from NADH dehydrogenase subunit 1 (ND1) di-
rectly stimulated PMN chemotaxis. This peptide binds to
MHC class Ib molecule H2-M3 in formylated as well as
nonformylated forms (25), and thus is denoted as MHC
binding peptide. It is of interest because mitochondria-
derived peptides, including ND1 peptides, are held to be lib-
erated from mitochondria and may play a role in accumula-
tion of phagocytic cells during tissue and cell lysis that can
accompany bacterial infection and/or ischemia–reperfusion
injury (26). This peptide gave a chemotaxis response at
concentrations as low as 1 nM (Fig. 2 A). The metaboli-
cally stable analogue of LXA4 and ATL (15(R/S)-methyl-
LXA4 [ATLa1], structure shown in Fig. 1), which resists
rapid enzyme inactivation (27) at equimolar concentration
to the peptide, dramatically inhibited the MHC peptide–
stimulated chemotaxis by z85% (Fig. 2 B). This lipoxin
analogue has structural properties of both LXA4 and ATL,
and alone at 10 nM did not induce chemotaxis (Fig. 2 A).
We also tested the synthetic surrogate peptide MMK-1
(LESIFRSLLFRVM, structure shown in Fig. 1) that was
recently reported to mobilize Ca21 via ALXR (previously
named FPRL-1; reference 28). This peptide also stimulated
PMN chemotaxis that peaked at 10 nM (Fig. 2 A) and was
inhibited by ATLa1 ( z78%, Fig. 2 B). Both the MHC
binding peptide and MMK-1 peptide activated PMNs as
monitored by microphysiometry, evoking a response con-
sistent with receptor-initiated increases in extracellular
acidification rates (Fig. 3, inset). Each peptide gave distinct
profiles. The lipid ATL stable analogue 15-epi-16-(para-
fluoro)-phenoxy-LXA4 (ATLa2, structure shown in Fig. 1)
did not increase the extracellular acidification rates of
PMNs but clearly blocked both MHC binding peptide–
and MMK-1–enhanced responses (Fig. 3). Hence, both
peptides evoke PMN responses that were blocked by ATL.
To examine whether the MHC binding peptide shares
recognition sites with LXA4 and ATL on PMNs, 3H-LXA4
was prepared (22; see Materials and Methods) for direct
ligand binding and competition. Of interest, MHC binding
peptide and MMK-1 directly competed with 3H-LXA4
(IC50 , 1029 M) (see below) but not 3H-LTB4 binding on
human PMNs (data not shown). To examine the direct
binding of this peptide with PMNs, an 125I-labeled MHC
binding peptide was prepared by iodination at the Tyr resi-
due. However, the 125I-labeled peptide did not promote
PMN chemotaxis, nor did it show specific binding (n 5 3,
data not shown), suggesting that the iodination altered1200 Lipid Mediators and Peptide Ligands of the Lipoxin A4 Receptor
MHC binding peptide recognition on PMNs. Together,
these findings suggest that LXA4/ATL and these peptides
share common recognition sites on PMNs, yet the peptides
evoke PMN responses distinct from those observed with
the lipid ligands.
ATL analogues are potent inhibitors of TNF-a–initiated
PMN infiltration into murine dorsal air pouch when ad-
ministrated either by topical intra–air pouch or systemic in-
travenous delivery (14). In this model, administration of
murine TNF-a induces a time-dependent increase in the
levels of macrophage inflammatory protein 1a, macrophage
inflammatory protein 2, and JE (the human homologue
of macrophage chemotaxis protein 1) in the pouch exudate
(29). The steady state mRNA levels of these chemokines
are also increased in exudate cells as well as in the tissue that
lines the air pouch. Hence, the initial phase of exudate for-
mation and leukocyte infiltration in this model (29) appears
to be predominantly chemokine driven. To test whether
the synthetic peptide MMK-1 shares this inhibitory prop-
erty, it was evaluated for its ability to impact exudate for-
mation and leukocyte trafficking in the murine air pouches
and directly compared with the action of LX. When in-
jected locally into the air pouch, the lipid mediator ana-
logue ATLa1 (10 mg/pouch) profoundly inhibited PMN
trafficking into these sites (z50%, P 5 0.03; Fig. 4 A). In
sharp contrast, the MMK-1 peptide at equal amounts (10
mg/pouch) did not give a statistically significant inhibition
(Fig. 4 A) and, moreover, neither the synthetic peptide
(MMK-1) (Fig. 4 A) nor lipid-derived mediator (16) given
alone at 10 mg per pouch stimulated PMN infiltration. At
much higher concentrations (e.g., 100 mg/pouch), we
noted that MMK-1 gave statistically significant PMN infil-
tration (Fig. 4 B, P 5 0.04). Together, these findings indi-
cate that ATL and MMK-1, although sharing common
recognition sites on PMNs, each displayed distinct actions
for controlling PMN trafficking in vivo.
To address the question of whether ATL as well as syn-
thetic peptides directly bind to recombinant ALXR, we
examined their ability to compete for specific 3H-LXA4 or
3H-LTB4 binding in HEK293 cells stably expressing either
human ALXR or human BLT (4, 15). Bioavailable stable
analogues of the lipid mediators LXA4 and ATL (e.g.,
ATLa1 and ATLa2) that exhibit potent anti-PMN actions in
vivo (7) competed for specific binding of 3H-LXA4 in
ALXR-transfected HEK293 cells (Fig. 5 A), with IC50 z
10211 to 10210 M, which exceed by .1,000-fold that of a
structurally related but biologically inactive isomer, 15-
deoxy-LXA4. The absence of a carbon-15 alcohol in LXA4
Figure 1. Structures of inhibitory lipid media-
tors and stimulatory peptides: LXA4, ATLa1,
ATLa2, MHC binding peptide, and MMK-1 sur-
rogate peptide.1201 Chiang et al.
and ATL results in essentially a biologically inactive prod-
uct (see reference 27) (IC50 z 1027 M). These findings in-
dicate that the 15-hydroxyl group of LXA4 is important for
receptor recognition (Fig. 5 A).
Of interest, both the MHC binding peptide and MMK-1
competed for specific binding of 3H-LXA4 at a level com-
parable to the inhibitory lipid ligands (IC50 z 10211 M).
These results with MHC binding peptide and MMK-1
demonstrate the direct interaction of these selective pep-
tides with ALXR (Fig. 5 B). For purposes of direct com-
parison, serum amyloid protein A (SAA), a proteolytic
product of the acute phase response (30), which was re-
cently shown to stimulate Ca21 mobilization and migration
of HEK293 cells expressing ALXR/FPRL-1 (31), also dis-
placed specific 3H-LXA4 binding. However, SAA required
a higher amount to achieve significant competition, with
an IC50 of 1028 to 1027 M (Fig. 5 B). These peptide ligands
were selective for ALXR, as peptides of random sequence
did not compete for 3H-LXA4 binding with ALXR (data
not shown). Along these lines, the bacterial chemotactic
surrogate peptide FMLP did not show displacement of 3H-
LXA4 binding with ALXR expressed in CHO cells at lev-
els ,1 mM (18). Neither LXA4 nor these peptides com-
peted for 3H-LTB4 specific binding to BLT, a related G
protein–coupled receptor (4), with BLT-transfected HEK293
cells (data not shown). Taken together, these findings pro-
vide the first direct evidence that ATLa as well as both the
MHC binding peptide and MMK-1 specifically interact
with recombinant ALXR.
Because both MMK-1 peptide and ATL competed at
the same receptor, it was of interest to determine whether
they could evoke cellular responses via recombinant
ALXR. To this end, we examined chemotaxis in CHO
cells expressing ALXR together with Gqo chimera.
MMK-1 at 1 nM gave a clear chemotaxis response when
compared directly to chemotaxis stimulated by another
peptide, FMLP, with CHO cells expressing its cognate re-
ceptor, the FPR (Fig. 6). FMLP stimulates CHO cell
chemotaxis with FPR (32) and was used here for the pur-
pose of direct comparison. FMLP did not stimulate chemo-
taxis with ALXR (not shown). ATLa1 at higher concentra-
Figure 2. ATLa inhibits PMN chemotaxis induced by MHC binding
peptide and surrogate MMK-1 peptide. (A) Freshly isolated human
PMNs were added to the upper compartment of a microchamber (5 3
104/well). Chemotaxis was initiated by addition of MHC binding peptide
(j), MMK-1 (d), or ATLa1 (s). (B) PMNs were incubated with vehicle
or ATLa1 (10 nM) for 30 min at 378C and added to the upper compart-
ment of a microchamber (5 3 104/well). Chemotaxis was initiated by ad-
dition of MHC peptide (black bar) or MMK-1 (gray bar) (1 nM) to the
lower compartment. Data represent the mean 6 SEM from three separate
healthy donors.
Figure 3. ATLa inhibits MHC binding peptide– and surrogate MMK-1
peptide–induced extracellular acidification in human PMNs. Human
PMNs (z2 3 105/chamber) were embedded in agar and placed in a mi-
crophysiometer. Extracellular acidification rate was normalized to base
line at t 5 0. PMNs were perfused with 1 mM of MHC binding peptide
(black bar) or MMK-1 (gray bar) in the presence or absence of ATLa2 (1
mM). Data are expressed as percent inhibition of extracellular acidification
rate by ATL (percent change of extracellular acidification rate in the ab-
sence of ATL is considered as 100%). Data represent n 5 3. Inset, Data
represent on-line microphysiometer tracings. Challenge of PMNs with
ATLa2 (s), MHC binding peptide (.), or MMK-1 (d) is indicated by
an arrow. Data are expressed as percent change of extracellular acidifica-
tion rate from n 5 3.1202 Lipid Mediators and Peptide Ligands of the Lipoxin A4 Receptor
tions evoked chemotaxis with ALXR (84% at 100 nM). In
CHO cells, ATLa-stimulated chemotaxis is likely the result
of different intracellular signaling events that follow ALXR
activation by ATLa in CHO cells versus PMNs. In this
context, it is of interest to point out that the same ligand–
receptor interaction (i.e., ALXR) in human monocytes
stimulates chemotaxis (33), as PMN responses are inhib-
ited. In the present experiments, ATLa1 at 10 nM did not
evoke significant chemotaxis (data not shown) but clearly
diminished MMK-1–stimulated chemotaxis (.80%) with
CHO-ALXR cells (Fig. 6, P , 0.01). This inhibition
proved to be ALXR dependent, and together these results
indicated that both MMK-1 and ATLa1 can activate the
same recombinant ALXR expressed in CHO cells.
Many G protein–coupled receptors contain N-glycosyla-
tion sites, and these sites are also present in ALXR at the
NH2 terminus (Asn-4) and second extracellular loop (Asn-
179) (17). Carbohydrate moieties of glycoprotein are im-
portant for processes such as intracellular trafficking and
surface expression. Both bacterial (Listeria monocytogenes)
and viral (retrovirus, herpes simplex virus) infection inter-
fere with normal N-glycosylation of the host cells (34–36).
Therefore, it was of interest to access the contribution of
N-glycosylation of ALXR to ligand class recognition. Re-
sults in Fig. 7 demonstrate that deglycosylation of ALXR
with N-glycosidase F (from Flavobacterium meningosepticum)
treatment of ALXR-transfected HEK293 cells did not dra-
matically alter LXA4 recognition, as LXA4 competed for
3H-LXA4 binding with deglycosylated ALXR at a level
(IC50 z 10211 M) comparable to that for native ALXR. In
contrast, both MHC binding peptide and MMK-1 peptides
displayed an z3 log order lower affinity (IC50 z 1028 M)
for the deglycosylated form of ALXR compared with the
native ALXR (see Fig. 5 B and Fig. 7). These results indi-
Figure 4. Surrogate peptide MMK-1 and ATLa1 display distinct actions
in vivo. 6-d murine dorsal air pouches were raised and injected locally
with (A) TNF-a (20 ng) plus MMK-1 or ATLa1, or TNF-a alone; or (B)
MMK-1 alone. After 4 h, pouches were lavaged and leukocytes were
enumerated. Data represent the mean 6 SEM from n 5 3 (*P 5 0.04,
**P 5 0.03).
Figure 5. LXs and peptides
specifically compete for 3H-
LXA4 on HEK293 cells. ALXR-
transfected HEK293 cells (5 3
106/ml) were incubated with
3H-LXA4 for 30 min at 48C in
the presence of an increasing
concentration of unlabeled LXA4
(j) or (A) ATLa1 (r), ATLa2
(d), 15-deoxy-LXA4 ( e), (B)
MMK-1 (n), MHC binding
peptide (s), or SAA (r). Bound
and unbound radioligands were
separated by filtration and spe-
cific binding was determined.
Data represent the mean 6 SEM
from duplicates of n 5 3.1203 Chiang et al.
Figure 6. ATLa1 as well as surrogate MMK-1 peptide evoke chemotaxis
via ALXR. CHO-FPR or CHO-Gqo-ALXR cells were pretreated with
vehicle alone (white, hatched, and black bars, respectively) or ATLa1 (10
nM, gray bar) for 30 min at 378C and added to the upper compartment of
a microchamber (5 3 104/well). Chemotaxis was initiated by addition of
FMLP (10 nM, white bar), ATLa1 (100 nM, hatched bar), or MMK-1 (1
nM, black and gray bars) to the lower compartment. Data were expressed
as percent chemotaxis above vehicle control. FMLP-evoked chemotaxis in
CHO-FPR is considered as 100%. Data represent the mean 6 SEM from
n 5 3 (*P , 0.01).
Figure 7. Deglycosylation of human ALXR attenuates ligand recogni-
tion for peptides but not LXA4. Human ALXR-transfected HEK293 cells
(5 3 105/ml) were pretreated with glycosidase F (1 U/ml) for 24 h at
378C and then incubated with 3H-LXA4 for 30 min at 48C in the pres-
ence of an increasing concentration of unlabeled LXA4 (j), MMK-1
(n), or MHC binding peptide (s). Bound and unbound radioligands
were separated by filtration and specific binding was determined. Data
represent the mean 6 SEM from n 5 3.
cate that N-glycosylation of ALXR is a key component for
peptide but not LXA4 recognition. It is likely that the pres-
ence of carbohydrates on this receptor favors the thermo-
dynamics and flexibility that enable recognition of these
specific peptides. Taken together, it is possible to envision
that the N-glycosylation state of the ALXR can determine
ligand binding in vivo and thus can potentially regulate
functional responses of leukocytes during microbial chal-
lenge or cell injury and contribute to inflammation resolu-
tion.
To evaluate the contributions of the major domains of
ALXR in interacting with either lipid mediators or peptide
ligands, chimeric receptors were constructed with human
ALXR and the recently cloned human BLT (4). ALXR
and BLT were selected for these chimeric constructs be-
cause leukotriene B4 is a potent chemoattractant (3), a “go”
signal, and LXA4 is an endogenous “stop” signal (7) that in-
hibits neutrophil chemotaxis, each by their interaction with
their specific responsive G protein–coupled receptors. Four
chimeric constructs with major domain exchange were pre-
pared (see Table II). The expression levels of these chimeras
were similar to those of wild-type receptors as determined
by reverse transcription PCR (data not shown). One chi-
meric receptor, denoted B/A299, with COOH terminus of
BLT replaced by the corresponding region of ALXR, dem-
onstrated threefold increase (Bmax z 30,000 sites/cell) of
specific 3H-LTB4 binding compared with wild-type BLT
(Bmax  z  9,600 sites/cell; cloned in this laboratory using
published DNA sequences [4]). Of interest, this chimera
gave a 60% decrease in extracellular acidification rate re-
sponses compared with wild-type BLT (n 5 3), suggesting
that the COOH terminus of BLT is important for BLT sig-
naling. In addition, the chimera denoted B/A254 displayed
specific binding with 3H-LXA4 with an affinity comparable
to that for wild-type ALXR (IC50 z 10211 M; Fig. 8, B and
C). This chimera B/A254, encompassing the third extracel-
lular loop, seventh transmembrane domain, and COOH
terminus of BLT that were replaced by the corresponding
regions of ALXR (see sequences in Fig. 8 A and illustration
in Fig. 8 B, inset), failed to specifically bind to 3H-LTB4. Of
interest, B/A254 showed decreased affinity to both MHC
binding peptide and MMK-1 (IC50 z 1029 M; Fig. 8 C).
Taken together, these results indicate that the third extra-
cellular loop as well as the seventh transmembrane do-
main are essential for ligand–receptor interaction for ALXR
and BLT.
ALXR shares z70% homology in deduced amino acid
sequences with FPR (5, 17) and z30% homology to the
BLT (see reference 4). The murine ALXR was identified
and cloned from the stimulated IL-21 NFS strain (13).
However, this receptor only binds 3H-FMLP with low af-
finity (Kd z 5 mM) and is selective for 3H-LXA4 by .3 log
orders of magnitude (18, 19). In addition, FMLP did not
compete for 3H-LXA4 binding with ALXR unless 1–100
mM was used (18). The first extracellular loop and its adja-
cent transmembrane domains of N-formyl peptide recep-
tors were found to be essential for high affinity FMLP
binding as demonstrated by site-directed mutagenesis (37)1204 Lipid Mediators and Peptide Ligands of the Lipoxin A4 Receptor
as well as FPR-ALXR chimeric receptors (38). For G pro-
tein–coupled receptors of lipid mediators such as cyclooxy-
genase products prostaglandin E2 and thromboxane A2, the
seventh transmembrane domain of their respective recep-
tors is important for ligand–receptor interactions (39). In
view of these results, together with our findings, it is likely
that certain natural peptides and endogenous lipid ligands
can share a common receptor, exemplified here by results
with the ligand requirements for interacting with the re-
ceptor that were different for lipid versus peptide ligand
recognition.
Recently, SAA was reported to stimulate ALXR-depen-
dent responses in vitro, but required high concentration
(i.e., micromolar) to evoke responses (31). Compared with
LXs, which act at ,1029 M (13, 17, 18), the structural fea-
tures that underlie the mimicry are of interest since their
IC50 are much higher than the peptides or ATL/LX. 125I-
SAA displayed specific binding on monocytes and HEK293
cells, expressing ALXR with apparent Kd of 45 and 64 nM,
respectively (31). These values, by comparison, are 1–2 log
orders of magnitude higher than those obtained with human
PMNs or CHO cells expressing ALXR, which gave high af-
finity binding for 3H-LXA4 with Kd at 0.5 and 1.7 nM, re-
spectively (see references 13, 17, 18, and 40). These values
for LXA4 are consistent with those obtained in the present
experiments with HEK293 cells stably expressing human
ALXR (Fig. 5).
Of interest, SAA levels in peripheral blood are increased
as much as 1,000-fold during inflammatory disorders (30),
and SAA, given its hydrophobicity, associates with high
density lipoproteins when levels exceed 1,000-fold basal val-
ues (41). Unlike lipid mediator autacoids such as LXA4 that
are rapidly (seconds to minutes) generated within local sites
of inflammation and act within these microenvironments
(7), SAA is biosynthesized predominantly in hepatocytes and
is released to peripheral blood where its levels slowly elevate
and persist for hours to days during an inflammatory re-
sponse. However, its function during the acute phase and in
inflammation remains to be determined (30). In this regard,
it is of interest that SAA inhibits the oxidative burst response
with N-formyl peptide–stimulated PMNs (42), suggesting
that SAA can, like LX and ATL (7), counteract PMN re-
sponses to cytokines or bacterial products (7, 14, 16, 42).
Thus, the relevance in vivo of SAA in controlling PMN re-
sponses via interactions with ALXR remains to be estab-
lished.
The F-peptide representing the V4–C4 region of HIV-1
envelop protein gp120 is also reported to activate
ALXR-expressing HEK293 cells as monitored by the ago-
nist promoting Ca21 mobilization and chemotaxis. How-
ever, there too the HIV-1 F-peptide only gives apparent
EC50 values in the micromolar range, yet subsequently
downregulates expression and function of CC chemokine
receptor 5 (CCR5) and CXC chemokine receptor 4
(CXCR4) in monocytes (43). In this regard, the actions of
LXA4 interaction at this receptor are directly opposite
when monocytes and PMNs are exposed to these ligands
in vitro (7, 27, 33) and in vivo (16) and require much
lower concentrations for recognition and activation. LXA4
and its analogues stimulate monocyte adherence via ALXR
Table II. Ligand Binding Properties of Recombinant ALXR, BLTR, and Chimeric Receptors
ALXR (bold)/BLTR (regular) chimeras were constructed and ligand binding assay was carried out as described in Materials and Methods. Nonspecific
binding was determined in the presence of 100 nM of unlabeled homoligand. NSB, no specific binding with 1 nM of radioligands (e.g., 3H-LXA4
or 3H-LTB4).1205 Chiang et al.
at ,1 nM (EC50 for analogues z 8 3 10211 M, EC50 for
LXA4 z 8 3 10210 M) (33) and inhibit PMN transmigra-
tion and adhesion at levels as low as 10210 M (27) by evok-
ing cell type–specific intracellular signaling responses. It is
noteworthy that LX and ATL analogue activation of
ALXR does not appear to involve either cAMP (not
shown) or the mobilization of appreciable levels of intra-
cellular Ca21 in either monocytes or neutrophils to mount
functional responses (27, 33). On the other hand, MMK-1
stimulates intracellular Ca21 mobilization (28) and in-
creases extracellular acidification rates in a receptor-depen-
dent fashion (Fig. 3). Although intracellular Ca21 mobili-
zation accompanies many leukocyte responses (1, 2), its
role in chemotaxis remains controversial in human periph-
eral blood neutrophils and monocytes (44).
Since LXs activate monocytes and inhibit PMNs (in
both murine and human cells; references 16, 33), it is
likely that LXs are mediators of resolution (45) where it is
well appreciated that monocyte recruitment plays a pivotal
role in wound healing (1). Hence, our results here empha-
size the importance of both temporal and local ligand-ini-
tiated signal transduction. In this context, with PMNs,
ALXR interaction with LX and ATL analogues regulates a
newly described polyisoprenyl phosphate signaling path-
way. ALXR activation reverses leukotriene B4–initiated
polyisoprenyl phosphate remodeling, leading to accumula-
tion of presqualene diphosphate, a potent negative intra-
cellular signal in PMNs that inhibits recombinant phos-
pholipase D and superoxide anion generation (46). The
complete intracellular signal transduction pathways initi-
ated after ALXR interaction with ATL and LX are the
subject of ongoing efforts, and the novel chimeric recep-
tors reported here open new avenues to examine intracel-
lular signals that are directly dependent on peptide versus
lipid ligands.
Our results demonstrate for the first time via direct evi-
dence that bioactive lipids as well as certain selective small
peptides/proteins can each serve as ligands at the same G
protein–coupled receptor, namely ALXR, but clearly act
with different affinity and/or distinct interaction sites
within the ALXR. It appears likely that the G protein in-
teractions evoked by ligand–receptor binding and their in-
tracellular amplification mechanisms are different for pep-
tide versus lipid ligands of ALXR, and hence they can
dictate different functional response in vivo. Also, these
results provide new evidence for the diversity of host rec-
ognition by PMNs and place these ligand-initiated re-
sponses as a “when and where” activity of PMNs or
monocytes in acute defense and wound healing (see refer-
ence 45). However, our data clearly indicating that ALXR
Figure 8. The seventh transmembrane segment and third extracellular loop of human ALXR are essential for LXA4 and peptide recognition: BLT/
ALXR chimeras. (A) Sequences of human ALXR (bold type), BLT (regular type), and B/A254 chimera at sixth transmembrane, third extracellular loop,
and seventh transmembrane. Inset shows e1–e3, representing the putative extracellular loops; TMI–VII, the transmembrane segments;and i1–i3, intracel-
lular loops for ALXR (bold line) or BLT (regular line). (B) ALXR-, BLT-, or B/A254-transfected HEK293 cells (5 3 105/ml) were incubated with 3H-
LXA4 (1 nM, black bar) or 3H-LTB4 (1 nM, white bar) in the absence or presence of 100 nM of unlabeled homoligand. (C) B/A254-transfected HEK293
cells were incubated with 3H-LXA4 (1 nM) in the presence of an increasing concentration of unlabeled LXA4 (j), MMK-1 (n), or MHC binding pep-
tide (s) for 30 min at 48C. Bound and unbound radioligands were separated by filtration and specific binding was determined. Data represent the mean 6
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is responsible for LXA4’s regulatory actions in leukocytes
do not preclude the involvement of additional plasma
membrane receptors and/or intracellular targets in LXA4
signal transduction. In addition to specific binding to
membrane surface receptors, we found that specific bind-
ing of labeled LXA4 was associated with subcellular frac-
tions including granules and nucleus (40). Along these
lines, it was recently reported that LXA4 binds to and acti-
vates the aryl hydrocarbon receptor, a ligand-activated
transcription factor, in a murine hepatoma cell line (47). It
is of interest in view of the present results that aryl hydro-
carbon receptor–deficient mice showed decreased accu-
mulation of lymphocytes in the spleen and lymph nodes,
suggesting an important role for aryl hydrocarbon receptor
in the immune system (48).
In summary, we identified the first endogenous non-LX
ligand for ALXR, namely MHC binding peptide, and
show that both the MHC binding peptide and surrogate
peptide MMK-1 evoked potential proinflammatory sig-
nals, whereas the endogenous lipid LXA4 gave antiinflam-
matory signals in vivo, yet they interact via the same G
protein–coupled receptor in vitro. LXA4, ATL, and these
peptides required different structural domains within the
receptor. In addition, N-glycosylations of ALXR may play
a role in switching receptor functions at local host defense
sites (e.g., between pro- and antiinflammatory or “stop/
go”), since N-glycosylation governs peptide but not lipid
recognition. Together, these findings indicate a high regi-
oselective array for ligand recognition by ALXR (i.e.,
demonstrated for both peptide and lipid ligands) and pro-
vide evidence for a novel role for the ALXR in modulat-
ing innate immunity, clearance, and/or resolution, and in
preventing PMN-mediated tissue injury.
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